The new product is a type of intramedullary nail, which is a rod that is inserted into a badly broken bone to keep the fragments together, according to the report.
The FDA clearance means that the agency feels that this device is similar to other products on the market and does not require clinical trials.
Read the Commercial Appeal’s report about NovaLign’s new intramedullary nail.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
